Literature DB >> 9426780

Endoscopically placed tubes for administration of enilconazole for treatment of nasal aspergillosis in dogs.

S M McCullough1, B C McKiernan, B S Grodsky.   

Abstract

An endoscopic method for administering commercial-grade enilconazole for treatment of nasal aspergillosis in dogs is described. Six dogs with confirmed nasal aspergillosis were anesthetized and feeding tubes were placed endoscopically into caudal sinuses. Commercial-grade enilconazole was infused into turbinates and sinuses for a total dwell time of 45 to 60 minutes. Dogs did not have recurrence of disease at final rhinoscopic examination and were markedly improved a mean of 13.3 months after treatment.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9426780

Source DB:  PubMed          Journal:  J Am Vet Med Assoc        ISSN： 0003-1488            Impact factor:   1.936


  4 in total

1.  Computed tomographic assessment of a new nonsurgical sinus trephination technique using a medical bone marrow drill.

Authors:  Victor Caudal; Elisabeth C Snead; Gregory S Starrak; Suresh Sathya; Cindy X Feng
Journal:  Can J Vet Res       Date:  2017-01       Impact factor: 1.310

2.  Efficacy of intrasinusal administration of bifonazole cream alone or in combination with enilconazole irrigation in canine sino-nasal aspergillosis: 17 cases.

Authors:  Frédéric Billen; Liz-Valery Guieu; Frédérique Bernaerts; Elise Mercier; Rachel Lavoué; Charlotte Tual; Dominique Peeters; Cécile Clercx
Journal:  Can Vet J       Date:  2010-02       Impact factor: 1.008

3.  Use of computed tomography to predict the outcome of a noninvasive intranasal infusion in dogs with nasal aspergillosis.

Authors:  Jimmy H Saunders; Luc Duchateau; Christophe Störk; Henri van Bree
Journal:  Can Vet J       Date:  2003-04       Impact factor: 1.008

4.  Minimally invasive treatment of sino-nasal aspergillosis in dogs.

Authors:  Clara Ballber; Tracy L Hill; Nick X Bommer
Journal:  J Vet Intern Med       Date:  2018-10-16       Impact factor: 3.333
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.